CA2501613A1 - Method and device for the non-invasive analysis of metabolic processes - Google Patents
Method and device for the non-invasive analysis of metabolic processes Download PDFInfo
- Publication number
- CA2501613A1 CA2501613A1 CA002501613A CA2501613A CA2501613A1 CA 2501613 A1 CA2501613 A1 CA 2501613A1 CA 002501613 A CA002501613 A CA 002501613A CA 2501613 A CA2501613 A CA 2501613A CA 2501613 A1 CA2501613 A1 CA 2501613A1
- Authority
- CA
- Canada
- Prior art keywords
- metabolism
- fluorescence
- light
- measuring
- optic cable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
The invention relates to a method and an arrangement for the non-invasive analysis of control and regulation processes in human and animal metabolism, in order to be able to draw conclusions about specific illnesses from the changes of individual metabolism parameters. Said method can be used in preventive analyses for the early detection of cancer, inflammatory diseases , and the determination of the anti-oxidant requirement, for the treatment control of individual illness images and the routine examination of occupational groups with specific physical and psychological stress. Accordi ng to the invention, biologically active substances relating to metabolism and having autofluorescence properties are selected from the native fluorescence spectrum in the wavelength range of between 287 nm and 640 nm, and are interlinked in biochemical and biophysical models, in order to describe control and regulation processes in the human body. The fluorescence spectra are detected by means of an optical measuring path consisting of a light source (5), a fibre optic cable (1) for supplying the stimulation light to t he measuring site, a fibre optic cable (2) for branching off the fluorescence light to the spectrometer (6), and an evaluation computer (7).
Description
VOSSIUS Et PARTNER 4 "METHOD AND DEVICE FOR THE NON-INVASIVE ANALYSIS OF METABOLIC
PROCESSES"
The invention relates to a method and an arrangement for the non-invasive analysis of control and regulation processes in human and animal metabolism, in order to be able to draw conclusions about specific illnesses from the changes of individual metabolism parameters.
Said method can be used in preventive analyses for the early detection of cancer, inflammatory diseases, and the determination of the need for antioxidants, for the therapy control of individual clinical pictures and the routine examination of occupational groups with specific physical and psychological stress.
For several years, analyses of fluorescence spectra have been known as highly accurate and very specific methods in basic research in biology as to transport processes by means of biological membranes and analyses in biomedicine as diagnostic auxiliary means and are currently in a steadily progressive developmental phase. The basis of the measuring methods is the knowledge of the properties of artificial fluorophores and the knowledge of the excitation and emission wavelengths of autofluorophores. A plurality of parameters relevant to metabolism such as tryptophan, adenosine triphosphate (ATP), guanosine triphosphate (GTP), nicotinamide adenine dinucleotide phosphate (NADP), nicotinamide adenine dinucleotide reduced (NADH), kynurenine, flavin adenine dinucleotide (FAD) and thromboxane have a so-called autofluorescence.
The determination of said autofluorescence has the advantage that the metabolism does not have to be supplied with non-physiological substances. For example, in the patent DE 35 42 167 A1, the changes of the autofluorescence of ascorbic acid during the oxidation process is used for the determination of the eye lens opacity in a non-invasive method.
Further works use the high native fluorescence of NADH for the detection of melanoma, DE 695 18 915 T2.
In the patent DE 32 10 593 A1, in an invasive method by means of an endoscope, the autofluorescence of the NADH is used for the determination of the oxido-reduction condition of organs.
VOSSIUS E't PARTNER 5 In the patent DE 19 53 51 14 A1, the varying autofluorescence of biological tissue in the emission range from 520 to 600 nm is used for the diagnosis of cancerous tissue, with no specific biologically relevant substance being referred to.
With this method, too, the measuring device has to be taken to the measuring site invasively by means of an endoscope.
After complex experiments, the fluorescence-spectrometric behaviour of biological tissues and organs was described with regard to a preventive cancer diagnosis in the patents US 59 83 125, US 57 69 081, US 53 69 496, US 60 91 985, US 60 80 584, US 63 46 101 B 1, US 2002 / 000 23 37 A 1, US 59 43 113, US 62 05 353 B1.
For the analysis, the intensities of individual substances such as tryptophan, NADH
and flavins, as well as the maximum fluorescence intensity in the wavelength range from 320 to 580 nm were considered. Additionally, the results of the Fourier analysis also considered.
In the analyses, the disadvantage could be determined that neither the use of the maximum fluorescence intensity in the wavelength range from 320 nm to 600 nm or the absolute fluorescence intensities of relevant metabolism parameters such as NADH, tryptophan, FAD and kynurenine nor the ratio of two substances such as NADH and kynurenine allows a clear separation between "healthy" and "cancerous".
Thus, e.g. a low ratio between the intensities of NADH and kynurenine is not only characteristic for cancer but all inflammatory diseases exhibit a similar ratio. This is not peculiar, since many cancerous diseases involve inflammations.
A further disadvantage of the invasive methods described above is the fact that by the stress load of the measuring process, a falsified momentary picture of the metabolism is given and no statements about metabolism regulatory processes are possible. Such a statement can only be made by measuring without stress, which can be repeated at short intervals or by measuring in a defined way as to time before and after a stress load.
The problem underlying the invention is the provision of a method and a device which allow a description of control and regulation processes in human and animal metabolism, in order to be able to draw conclusions about specific clinical pictures in the case of changes in these processes. The method is intended to make the actual measuring process non-invasive and quickly repeatable in order not to cause VOSSIUS >rt PARTNER 6 a stress load by the measuring process.
According to the invention, the problem is solved by the features disclosed in the patent claims.
The advantages of the invention are the non-invasive measuring of fluorescence spectra and the lack of stress guaranteed thereby. Due to this measuring process, repeated measuring can take place at very short intervals and, thus, regulation processes in the metabolism can be recognised. By changes of these regulation processes under defined stress conditions, conclusions can be drawn about pathological changes of the organism.
In the following, the invention is illustrated in detail by means of an embodiment.
The enclosed figures show:
Fig. 1 Block diagram of the recordation of the measurement readings Fig. 2 Native fluorescence spectra Fig. 3 Illustration of results of a simple biochemical model as selection stage Fig. 4 Result of the separation of cancer diseases and inflammatory diseases Fig. 5 Selection using the emission wavelengths 509 nm and 495 nm By means of an optical measured section according to Fig. 1 consisting of a fibre optic cable 1 for the supply of the excitation light ray and an optic fibre cable 2 with collimator 3 for the diversion of the measuring signal, ['] is put at a suitable site of the body, preferably the crease between the thumb and the index finger. Both fibre optic cables 1; 2 are located in a carrier which is ergonomically formed, preferably a handpiece 4, and their outlets are preferably located vertically to each other.
A source of light 5 consisting of a laser or a controlled Xe flashlamp with a downstream monochromator or filter, produces the light for the excitation of the autofluorescence and is directed to the measuring site via the fibre optic cable 1.
The wavelengths of the excitation light are preferably 287 nm, 305 nm, 326 nm and ~ Translator's note: Sentence incomplete.
VOSSIUS 8t PARTNER 7 337 nm.
The fluorescent light emitted at the measuring site due to the excitation is collected by the collimator 3 and coupled into the fibre optic cable 2 and directed to a spectrometer 6. The spectrometer can have both a CCD line sensor and a photomultiplier with an upstream acusto-optical monochromator as transducer unit.
The optical spectra which have been converted into electrical signals in the spectrometer 6, are now saved in a corresponding computing structure 7.
The fluorescence spectra saved in the computer consisting of the recorded wavelengths in the range of 287 nm to 600 nm and the corresponding fluorescence intensities, are prepared for analysis in a suitable table format.
Fig. 2 shows examples of said native spectra.
The value combinations (wavelength and fluorescence intensity) for metabolism-relevant, biologically active substances such as ATP, GTP, tryptophan, orotic acid, NADP, NADH, FAD etc. are selected from these tables. The excitation wavelengths and emission wavelengths of these substances were determined in complex pilot tests. Since different skin structures and skin components do not allow the use of the absolute values, further analysis can only take place with relative values. It is therefore necessary to determine value pairings of the relevant biologically active substances and to interrelate them in biophysical and biochemical models.
These models contain substances which react with each other during the metabolism processes, are converted into each other and/or affect each other in their concentration and reactivity.
Fig. 3 shows the illustration of the result of a simple biochemical model which is used as the first selection stage of diagnosis, and which consists of the combination of NADH, kynurenine, FAD, NADP and thromboxane. This illustration demonstrates that even the use of five metabolism-relevant substances does not suffice to separate cancer diseases from inflammatory diseases. The first selection stage is only suitable to differentiate between "ill" and "healthy".
Subsequently, further selection stages take place in order to differentiate between inflammatory diseases and cancer diseases and also to detect a differentiation amongst the inflammatory diseases.
Fig. 4 shows a separation between cancer diseases and treated cancer diseases VOSSIUS &t PARTNER 8 and inflammatory diseases.
The analysis of the spectra by selection of the diseases by means of biophysical and biochemical models on the basis of biologically active substances known takes place at the same time as the analysis by means of self-learning systems which search for differences in the spectra of healthy probands and patients without using a known value pairing (wavelength and intensity) of biologically active substances.
Fig. 5 shows an additional selection at the wavelengths 509 nm and 495 nm, wherein the emitting substances have not been known so far, however, the use of this selection shows to be successful.
VOSSIUS St PARTNER
List of reference numbers 1. fibre optic cable for the supply of the excitation light 2. fibre optic cable for the diversion of the fluorescent light 3. collimator 4. handpiece 5. source of light 6. spectrometer 7. computing structure
PROCESSES"
The invention relates to a method and an arrangement for the non-invasive analysis of control and regulation processes in human and animal metabolism, in order to be able to draw conclusions about specific illnesses from the changes of individual metabolism parameters.
Said method can be used in preventive analyses for the early detection of cancer, inflammatory diseases, and the determination of the need for antioxidants, for the therapy control of individual clinical pictures and the routine examination of occupational groups with specific physical and psychological stress.
For several years, analyses of fluorescence spectra have been known as highly accurate and very specific methods in basic research in biology as to transport processes by means of biological membranes and analyses in biomedicine as diagnostic auxiliary means and are currently in a steadily progressive developmental phase. The basis of the measuring methods is the knowledge of the properties of artificial fluorophores and the knowledge of the excitation and emission wavelengths of autofluorophores. A plurality of parameters relevant to metabolism such as tryptophan, adenosine triphosphate (ATP), guanosine triphosphate (GTP), nicotinamide adenine dinucleotide phosphate (NADP), nicotinamide adenine dinucleotide reduced (NADH), kynurenine, flavin adenine dinucleotide (FAD) and thromboxane have a so-called autofluorescence.
The determination of said autofluorescence has the advantage that the metabolism does not have to be supplied with non-physiological substances. For example, in the patent DE 35 42 167 A1, the changes of the autofluorescence of ascorbic acid during the oxidation process is used for the determination of the eye lens opacity in a non-invasive method.
Further works use the high native fluorescence of NADH for the detection of melanoma, DE 695 18 915 T2.
In the patent DE 32 10 593 A1, in an invasive method by means of an endoscope, the autofluorescence of the NADH is used for the determination of the oxido-reduction condition of organs.
VOSSIUS E't PARTNER 5 In the patent DE 19 53 51 14 A1, the varying autofluorescence of biological tissue in the emission range from 520 to 600 nm is used for the diagnosis of cancerous tissue, with no specific biologically relevant substance being referred to.
With this method, too, the measuring device has to be taken to the measuring site invasively by means of an endoscope.
After complex experiments, the fluorescence-spectrometric behaviour of biological tissues and organs was described with regard to a preventive cancer diagnosis in the patents US 59 83 125, US 57 69 081, US 53 69 496, US 60 91 985, US 60 80 584, US 63 46 101 B 1, US 2002 / 000 23 37 A 1, US 59 43 113, US 62 05 353 B1.
For the analysis, the intensities of individual substances such as tryptophan, NADH
and flavins, as well as the maximum fluorescence intensity in the wavelength range from 320 to 580 nm were considered. Additionally, the results of the Fourier analysis also considered.
In the analyses, the disadvantage could be determined that neither the use of the maximum fluorescence intensity in the wavelength range from 320 nm to 600 nm or the absolute fluorescence intensities of relevant metabolism parameters such as NADH, tryptophan, FAD and kynurenine nor the ratio of two substances such as NADH and kynurenine allows a clear separation between "healthy" and "cancerous".
Thus, e.g. a low ratio between the intensities of NADH and kynurenine is not only characteristic for cancer but all inflammatory diseases exhibit a similar ratio. This is not peculiar, since many cancerous diseases involve inflammations.
A further disadvantage of the invasive methods described above is the fact that by the stress load of the measuring process, a falsified momentary picture of the metabolism is given and no statements about metabolism regulatory processes are possible. Such a statement can only be made by measuring without stress, which can be repeated at short intervals or by measuring in a defined way as to time before and after a stress load.
The problem underlying the invention is the provision of a method and a device which allow a description of control and regulation processes in human and animal metabolism, in order to be able to draw conclusions about specific clinical pictures in the case of changes in these processes. The method is intended to make the actual measuring process non-invasive and quickly repeatable in order not to cause VOSSIUS >rt PARTNER 6 a stress load by the measuring process.
According to the invention, the problem is solved by the features disclosed in the patent claims.
The advantages of the invention are the non-invasive measuring of fluorescence spectra and the lack of stress guaranteed thereby. Due to this measuring process, repeated measuring can take place at very short intervals and, thus, regulation processes in the metabolism can be recognised. By changes of these regulation processes under defined stress conditions, conclusions can be drawn about pathological changes of the organism.
In the following, the invention is illustrated in detail by means of an embodiment.
The enclosed figures show:
Fig. 1 Block diagram of the recordation of the measurement readings Fig. 2 Native fluorescence spectra Fig. 3 Illustration of results of a simple biochemical model as selection stage Fig. 4 Result of the separation of cancer diseases and inflammatory diseases Fig. 5 Selection using the emission wavelengths 509 nm and 495 nm By means of an optical measured section according to Fig. 1 consisting of a fibre optic cable 1 for the supply of the excitation light ray and an optic fibre cable 2 with collimator 3 for the diversion of the measuring signal, ['] is put at a suitable site of the body, preferably the crease between the thumb and the index finger. Both fibre optic cables 1; 2 are located in a carrier which is ergonomically formed, preferably a handpiece 4, and their outlets are preferably located vertically to each other.
A source of light 5 consisting of a laser or a controlled Xe flashlamp with a downstream monochromator or filter, produces the light for the excitation of the autofluorescence and is directed to the measuring site via the fibre optic cable 1.
The wavelengths of the excitation light are preferably 287 nm, 305 nm, 326 nm and ~ Translator's note: Sentence incomplete.
VOSSIUS 8t PARTNER 7 337 nm.
The fluorescent light emitted at the measuring site due to the excitation is collected by the collimator 3 and coupled into the fibre optic cable 2 and directed to a spectrometer 6. The spectrometer can have both a CCD line sensor and a photomultiplier with an upstream acusto-optical monochromator as transducer unit.
The optical spectra which have been converted into electrical signals in the spectrometer 6, are now saved in a corresponding computing structure 7.
The fluorescence spectra saved in the computer consisting of the recorded wavelengths in the range of 287 nm to 600 nm and the corresponding fluorescence intensities, are prepared for analysis in a suitable table format.
Fig. 2 shows examples of said native spectra.
The value combinations (wavelength and fluorescence intensity) for metabolism-relevant, biologically active substances such as ATP, GTP, tryptophan, orotic acid, NADP, NADH, FAD etc. are selected from these tables. The excitation wavelengths and emission wavelengths of these substances were determined in complex pilot tests. Since different skin structures and skin components do not allow the use of the absolute values, further analysis can only take place with relative values. It is therefore necessary to determine value pairings of the relevant biologically active substances and to interrelate them in biophysical and biochemical models.
These models contain substances which react with each other during the metabolism processes, are converted into each other and/or affect each other in their concentration and reactivity.
Fig. 3 shows the illustration of the result of a simple biochemical model which is used as the first selection stage of diagnosis, and which consists of the combination of NADH, kynurenine, FAD, NADP and thromboxane. This illustration demonstrates that even the use of five metabolism-relevant substances does not suffice to separate cancer diseases from inflammatory diseases. The first selection stage is only suitable to differentiate between "ill" and "healthy".
Subsequently, further selection stages take place in order to differentiate between inflammatory diseases and cancer diseases and also to detect a differentiation amongst the inflammatory diseases.
Fig. 4 shows a separation between cancer diseases and treated cancer diseases VOSSIUS &t PARTNER 8 and inflammatory diseases.
The analysis of the spectra by selection of the diseases by means of biophysical and biochemical models on the basis of biologically active substances known takes place at the same time as the analysis by means of self-learning systems which search for differences in the spectra of healthy probands and patients without using a known value pairing (wavelength and intensity) of biologically active substances.
Fig. 5 shows an additional selection at the wavelengths 509 nm and 495 nm, wherein the emitting substances have not been known so far, however, the use of this selection shows to be successful.
VOSSIUS St PARTNER
List of reference numbers 1. fibre optic cable for the supply of the excitation light 2. fibre optic cable for the diversion of the fluorescent light 3. collimator 4. handpiece 5. source of light 6. spectrometer 7. computing structure
Claims (10)
1. Method for the non-invasive analysis of control and regulation processes in human and animal metabolism for the diagnosis of diseases and preventive examinations, for routine examinations of occupational groups and sports people with high levels of physical and psychological stress, for therapy control, for the process of dialysis and apheresis treatment and for the determination of the need for antioxidants, characterised in that the substances relevant to the metabolism, which react with each other during metabolism processes, are converted into each other and/or affect each other in their concentration and reactivity and which exhibit an (endogenous) autofluorescence, are determined as to their fluorescence intensity and thus indirectly to their concentration, are put into mathematical relation to each other according to biochemical requirements and compared to indication-specific models defining the metabolism state of diseases.
2. The method according to claim 1, characterised in that the indication-specific models consist of several (however at least 6) calculated values corresponding to the respective metabolism state of the clinical picture and are calculated from the fluorescence intensities by means of mathematical combinations such as quotients, products, sums, subtractions or more complex formulas.
3. The method according to claims 1 and 2, characterised in that the fluorescence intensities are measured in the wavelength range of 287 nm to 800 nm, preferably from 340 nm to 600 nm, for metabolism-relevant substances the emission wavelengths of which are known, preferably ATP, GTP, FAD, NADH, NADP, kynurenine, orotic acid, thromboxane and tryptophan.
4. The method according to claims 1 to 3, characterised in that the measuring of the fluorescence intensities takes place at a defined point in time and/or at defined intervals so that control and regulation processes are detected by means of these process measurements.
5. The method according to claims 1 to 4, characterised in that at a defined point in time of measuring, the patient suffers psychological or physiological stress, the fluorescence intensities are measured several times before and after the stress load and the regulation process in the metabolism is determined.
6. The method according to claims 1 to 5, characterised in that biologically active substances exhibiting an autofluorescence are stimulated for emission by means of light with an excitation wavelength of 287 nm to 340 nm, preferably nm, in the cellular and intercellular area.
7. The device according to claims 1 to 6, characterised in that the areas stimulated to emit fluorescence are located at the earlobe, the hand and the nostril, preferably the crease between the thumb and index finger.
8. Device for carrying out the method according to the preceding claims, characterised in that the monochromatic light necessary for the excitation is produced by means of a source of light (5), preferably a laser or an Xe flashlamp with an optical filter and directed to the site of measurement via a fibre optic cable (1).
9. The device according to claim 8, characterised in that the emitted light of the autofluorophore is directed, via a fibre optic cable (2), from the site of measuring to a spectrometer (6) comprising a CCD line sensor or an acusto-optical monochromator and photomultiplier and after digitalisation of the values measured, the emission intensities are analysed by suitable computing structures (7).
10. The device according to claims 8 to 9, characterised in that the analysis in the computing structures takes place by means of mathematical models of biological regulation systems and/or self-learning systems.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10246967.9 | 2002-10-09 | ||
| DE2002146967 DE10246967A1 (en) | 2002-10-09 | 2002-10-09 | Non-invasive and/or invasive investigation of the control and regulating processes of material exchange comprises determining substances relevant for material exchange by fluorescence intensity and concentration |
| PCT/DE2003/003278 WO2004032734A1 (en) | 2002-10-09 | 2003-10-02 | Method and device for the non-invasive analysis of metabolic processes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2501613A1 true CA2501613A1 (en) | 2004-04-22 |
Family
ID=32038351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002501613A Abandoned CA2501613A1 (en) | 2002-10-09 | 2003-10-02 | Method and device for the non-invasive analysis of metabolic processes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1551283A1 (en) |
| JP (1) | JP2006501906A (en) |
| CA (1) | CA2501613A1 (en) |
| DE (1) | DE10246967A1 (en) |
| WO (1) | WO2004032734A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160151003A1 (en) * | 2013-09-27 | 2016-06-02 | Fujifilm Corporation | Optical measurement device |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009536053A (en) * | 2006-05-05 | 2009-10-08 | メヴィテック・ゲーエムベーハー | Apparatus and method for testing and evaluating biologically active and / or activatable substances |
| DE102006021343A1 (en) * | 2006-05-05 | 2007-11-08 | Mevitec Gmbh | Biological cloth`s e.g. animal body cloth, optical examining or analysis device, has measuring surface section placed at upper and/or lower side of structural unit, where section is adapted to shape and dimension of cloth to be examined |
| DE102008011013B4 (en) * | 2008-02-25 | 2014-11-13 | Mevitec Gmbh | Method and device for complex metabolic analysis |
| DE102010023486A1 (en) * | 2010-06-11 | 2011-12-15 | B. Braun Avitum Ag | Detection device and method |
| CN102641117B (en) * | 2011-02-21 | 2015-08-19 | 南台科技大学 | A kind of non-intrusion type human metabolism's state measuring device and method |
| PL226889B1 (en) * | 2011-05-31 | 2017-09-29 | Politechnika Łódzka | Method and system for assessing the endothelial function |
| KR101335321B1 (en) * | 2011-12-26 | 2013-12-02 | 김영기 | Active oxygen analyzer |
| DE102012002086A1 (en) * | 2012-02-06 | 2013-08-08 | Carl Zeiss Meditec Ag | A method of examining biological tissue and devices for examining and treating the tissue |
| DE102020108957B4 (en) | 2020-03-31 | 2021-10-07 | Otto-Von-Guericke-Universität Magdeburg | Apparatus, method and computer program for measuring fluorescence |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6645796A (en) * | 1995-08-01 | 1997-02-26 | Medispectra, Inc. | Optical microprobes and methods for spectral analysis of materials |
| US5769081A (en) * | 1996-03-18 | 1998-06-23 | The Research Foundation Of City College Of New York | Method for detecting cancerous tissue using optical spectroscopy and fourier analysis |
| DE19612536A1 (en) * | 1996-03-29 | 1997-10-02 | Freitag Lutz Dr | Arrangement and method for diagnosing malignant tissue by fluorescence observation |
| US6405070B1 (en) * | 1998-06-16 | 2002-06-11 | Bhaskar Banerjee | Detection of cancer using cellular autofluorescence |
| US6377841B1 (en) * | 2000-03-31 | 2002-04-23 | Vanderbilt University | Tumor demarcation using optical spectroscopy |
| AU2001293592A1 (en) * | 2000-10-06 | 2002-04-15 | Peter R. Herman | Multi-spectral fluorescence imaging and spectroscopy device |
-
2002
- 2002-10-09 DE DE2002146967 patent/DE10246967A1/en not_active Ceased
-
2003
- 2003-10-02 EP EP03775045A patent/EP1551283A1/en not_active Withdrawn
- 2003-10-02 JP JP2004542184A patent/JP2006501906A/en active Pending
- 2003-10-02 CA CA002501613A patent/CA2501613A1/en not_active Abandoned
- 2003-10-02 WO PCT/DE2003/003278 patent/WO2004032734A1/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160151003A1 (en) * | 2013-09-27 | 2016-06-02 | Fujifilm Corporation | Optical measurement device |
| EP3051275A4 (en) * | 2013-09-27 | 2016-10-05 | Fujifilm Corp | Optical measurement device |
Also Published As
| Publication number | Publication date |
|---|---|
| DE10246967A1 (en) | 2004-04-22 |
| WO2004032734A1 (en) | 2004-04-22 |
| EP1551283A1 (en) | 2005-07-13 |
| JP2006501906A (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11656448B2 (en) | Method and apparatus for quantitative hyperspectral fluorescence and reflectance imaging for surgical guidance | |
| US20200155004A1 (en) | Device, system and method for quantifying fluorescence and optical properties | |
| US10463286B2 (en) | Determination of tissue oxygenation in vivo | |
| DE102008011013B4 (en) | Method and device for complex metabolic analysis | |
| Smirnova et al. | Collagen as in vivo quantitative fluorescent biomarkers of abnormal tissue changes | |
| Dunaev et al. | Laser reflectance oximetry and Doppler flowmetry in assessment of complex physiological parameters of cutaneous blood microcirculation | |
| CA2501613A1 (en) | Method and device for the non-invasive analysis of metabolic processes | |
| Ruiz et al. | Smartphone fluorescence imager for quantitative dosimetry of protoporphyrin-IX-based photodynamic therapy in skin | |
| Xi et al. | Hybrid photoacoustic and electrophysiological recording of neurovascular communications in freely-moving rats | |
| Dunaev | Wearable devices for multimodal optical diagnostics of microcirculatory-tissue systems: application experience in the clinic and space | |
| CN101529228B (en) | Device and method for examining and evaluating a biologically active and/or activatable substance | |
| US20230280577A1 (en) | Method and apparatus for quantitative hyperspectral fluorescence and reflectance imaging for surgical guidance | |
| Ellerby et al. | Validation of a spectroscopic sensor for the continuous, noninvasive measurement of muscle oxygen saturation and pH | |
| Tellis et al. | Use of diffuse correlation spectroscopy to measure brain blood flow differences during speaking and nonspeaking tasks for fluent speakers and persons who stutter | |
| CN108007910B (en) | Depth-sensitive optical fiber probe for in-situ measurement of fluorescence spectrum and back-scattered light spectrum of skin tissue | |
| RU2663938C1 (en) | Device for optical diagnostics of blood supply and life support of bio-tissues | |
| RU2547790C1 (en) | Method of evaluating tolerance to physical loading by measurement of autofluorescent properties of skin | |
| Volodymyr et al. | OPTICAL PROPERTIES OF BLOOD IN ACUTE PANCREATITIS | |
| Lee et al. | Novel diffuse optics system for continuous tissue viability monitoring: extended recovery in vivo testing in a porcine flap model | |
| RU2657294C1 (en) | Device for quantitative estimation of fluorescence and optical characteristics of tissue in vivo | |
| Rogatkin et al. | The way to universal and correct medical presentation of diagnostic informations for complex spectrophotometry noninvasive medical diagnostic systems | |
| Prince et al. | Modelling of Diseased Tissue Diffuse Reflectance and Extraction of Optical Properties | |
| Davies et al. | Non-invasive photonics-based diagnostic imaging, monitoring, and light delivery techniques for the recognition, quantification, and treatment of malignant and chronic inflammatory conditions | |
| Hajizadeh-Saffar | The non-invasive quantification of cutaneous haemoglobin and its oxygenation by reflectance spectrophotometry | |
| Borisova et al. | Optical biopsy–tool for initial cancer diagnosis and monitoring of therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |